Sanofi Pasteur Influenza Vaccines

Sanofi Pasteur believes in a world in which no one suffers or dies from a vaccine-preventable disease.

We Are Focused on Helping to Prevent as Much Influenza Disease As Possible

Communication Objectives

- Increase public awareness of the need for influenza vaccines
- Vaccinate as many people as possible and extend the immunization season
- Change the influenza conversation from symptoms to influenza disease and its outcomes
- Give the availability of the vaccine proven to help prevent influenza disease
- Impact a greater understanding the development of new vaccines

COVID-19 Pandemic Has Increased Flu Demand and Requires a Shift in Immunization Approaches and Timing of Vaccination

Driving patient visits, optimizing customer interactions, and supporting alternate immunization approaches will be required to maximize in-season immunization pull-through.

Sanofi Pasteur’s Legacy Of Innovating and Investing Continues

- 2019–20 Season: Delivered nearly 70 million doses to the US
  - Close to 20M Fluzone High-Dose (Influenza Vaccine), representing nearly 2/3 of immunizations in the targeted population
  - Continued growth Flublok Quadrivalent (Influenza Vaccine) with 2x increase in distribution
  - Fluzone Quadrivalent (Influenza Vaccine) continues to be the most used influenza vaccine brand
- 2020–21 Season: Increase production by 10% and manufacturing over 75 million doses to help protect Americans of all ages
  - Fluzone High-Dose, Flublok Quadrivalent now approved
  - Continued growth in differentiated flu portfolio, Fluzone High-Dose Quadrivalent and Flublok Quadrivalent vaccines

2019-20 Influenza Summit Priorities to Extend the Season Resulted in More Adults Getting Vaccinate Later in the Immunization Season

Source: IQVIA National Pharmacy Claims, includes Retail & Medical Issue through Week 46

2020 NAIIS Virtual Summit – 5/21/2020